par Smyth, J F;Aamdal, S;Awada, Ahmad 
;Dittrich, C;Caponigro, F;Schöffski, P;Gore, Martin;Lesimple, Thierry;Djurasinovic, N;Baron, Benoît;Ravic, M;Fumoleau, Pierre;Punt, Cornelis;EORTC New Drug Development and Melanoma Groups,
Référence Annals of oncology, 16, 1, page (158-161)
Publication Publié, 2005-01
;Dittrich, C;Caponigro, F;Schöffski, P;Gore, Martin;Lesimple, Thierry;Djurasinovic, N;Baron, Benoît;Ravic, M;Fumoleau, Pierre;Punt, Cornelis;EORTC New Drug Development and Melanoma Groups, Référence Annals of oncology, 16, 1, page (158-161)
Publication Publié, 2005-01
Article révisé par les pairs
| Résumé : | E7070 is a synthetic chloro-indolyl sulphonamide that is being developed as an anti cancer agent. In this phase II study, 28 patients with metastatic melanoma received 700 mg/m(2) of E7070 as a 60-min infusion repeated every 3 weeks. Although therapy was well tolerated, with one patient receiving 14 courses of treatment, there were only minor responses on independent radiological review. E7070 does not warrant further development as a single agent for the treatment of metastatic melanoma. |
